RDB07826 - pGL3-AID R1 del.-03

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pGL3-AID R1 del.-03 (#RDB07826)

Reporter construct of mouse Aicda locus, position -1075 to +101.

Clone info.	Reporter construct of mouse Aicda locus with firefly luciferase. Cloned position, -1075 to +101.
Comment	Nat. Immunol. (2010) 2, 148-154, Fig. 1a.
Vector backbone	pGL3 (Plasmid)
Selectable markers	Amp^r
Gene/insert name	Mouse Aicda genomic DNA
Depositor\|Developer	Honjo, Tasuku \|

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
MTA, for use for for-profit purpose [Word]
Please visit Information of Request for Distribution.[link]

Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature(s) designated by the DEPOSITOR is requested. (Nat. Immunol., 11, 148-154 (2010)). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
Additional terms and conditions:
The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] MTA, for use for for-profit purpose [Word] Please visit Information of Request for Distribution.[link]
Terms and conditions for distribution	In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature(s) designated by the DEPOSITOR is requested. (Nat. Immunol., 11, 148-154 (2010)). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 提供同意書 (MTA, 営利目的用)[Word] 手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件	利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Nat. Immunol., 11, 148-154 (2010))。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。　学術機関の学術研究に限る。　営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。　利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 MTAに書く付加的使用条件：本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

必要書類

提供依頼書

[依頼書の記入例

]
提供同意書 (MTA, 非営利学術目的用)[Word

] [MTAの記入例

]
提供同意書 (MTA, 営利目的用)[Word

]
手続きの概要は、「提供申込みについて[link]」をご覧ください。

MTAに書く使用条件

利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Nat. Immunol., 11, 148-154 (2010))。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。　学術機関の学術研究に限る。　営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。　利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。
MTAに書く付加的使用条件：
本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB07826	pGL3-AID R1 del.-03	DNA solution	JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pGL3-AID R1 del.-03 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07826).

Reference section:

Tran, T.H., Nakata, M., Suzuki, K., Begum, N.A., Shinkura, R., Fagarasan, S., Honjo, T., Nagaoka, H., B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat. Immunol., 11, 148-154 (2010). PMID 19966806. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB07826_A4Gi.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: pGL4-4174F Sequence file: RDB07826_A4Gia.seq
>07826_07826_A4Gi_pGL4-4174F_B11_05.ab1 1 AGGAAGGTCA GACATTTCTC TATCGATAGG TACCGAGCTC TTACGCGTGC TAGCCCGGGC 61 TCGAGAGACC AGCCAGAGGA GCTACATAAT GACACCCTAT TTTAAAAAAG GAAGGGAAGG 121 AAGGAAGGAA GGAAGGAAGG AAGGAAGGAA GGAAGGAAGC AAAGGATGTT CTTCCAGATG 181 ATCAGGGTTC AGATCCCAGC AAGCACACAT GGTGGCTTTC AACTGCCTGC TGGTCCTCTG 241 CAATAGAAGT AAGTGCTCTT AATCACTGGG CCAGCTCTCC AGGCCTCCAG TAAGGTATTT 301 TTAATGAGGA AAAGGAGTTC TTTTTTTTTT TAATACTTTT TGACACACAC ACACACACAA 361 AATTAAAATA AATCACTTTT TGGTGCAAGC AACTAGTCTT TCTAGCTATC TTATAATGTC 421 ATTTTAAAAA AAGAAAAATA TATTAGAGAA TTGGGAGGCT AAAGTTCACT CTCTGGATGC 481 TGTGGTGGTC AACCCCCATC TCTACTGAGG CATAAAACTG AGTGTAACAA ACGGAAGGAA 541 CAGATACTGT AAGTTCAAGA AGCACAAGAT GCAACTGAAG TGCCATTTAA GGCCACTTTA 601 AGTCACTATG ACTGCTATCA TTCTTGTTAT CATAGTTTTA AAATTAGGAA GTATGCACAG 661 ACCTTAGGTG TGATACCCGG GACCACACAC ACACACACAC ACACTCACAG AGCTCATTAT 721 CATGATACCA ATGTGAGAAG TGTCCAGTGC TATTGTCTCC TGATCTTTGT TACCTGTGAT 781 ACCTGGGCTG GCTTTTTAGA GGAACAGCCT CGAAGGAAGT TGGACATTAA GCATGAGCAG 841 AACTGGCCCC CCCCCCCAAT CATTTAATCC GTGTGGCTTT GCCCACCACA GCCCCGCCCA 901 TCTTTACTGG ACCCAACCCA GGAGGCAGAT GTTGGATACC TGGTGGTAGT GATGCTGTCG 961 TGGGGGAGGA GCCCACAAGA GCAAGCTCAG ATTTGAATGC CAGGGGCCAG TGCTCTGTCA 1021 CACAACAGCA CTGAAGCAGC CCTTGCTTGA AGCAAGCTTC CTTTGGCTAG ACCTTGAGGG 1081 AGTCCAAGAA AGTTCACGCT GGAGACGATC CATGCTAGAA CGCAAAACAT AATGACGACC 1141 GGCGCATTCT ATCGCTGCAA GAATGGGAAC CGCCTTG //
Primer: Luc_R Sequence file: RDB07826_A4Gib.seq
>07826_07826_A4Gi_Luc_R_C11_08.ab1 1 CATCGTTTCA GGAACAGGGC GTATCTCTTC ATAGCCTTAT GCAGTTGCTC TCCAGCGGTT 61 CCATCTTCCA GCGGATAGAA TGGCGCCGGG CCTTTCTTTA TGTTTTTGGC GTCTTCCATG 121 GATCGGTCTC CAGCGTGACT TTCTTGACTC CCTCAAAGTC TTAGGCCAAA GGAAGCTTGC 181 TTCAAGCAAG GCTGCTTCAG TGCTGTTGTG TGACAGAGCA CTGGCCCCTG GCATTCAAAT 241 CTGAGCTTGC TCTTGTGGGC TCCTCCCCCA CGACAGCATC ACTACCACCA GGTATCCAAC 301 ATCTGCCTCC TGGGTTGGGT CCAGTAAAGA TGGGCGGGGC TGTGGTGGGC AAAGCCACAC 361 GGATTAAATG ATTGGGGGGG GGGGCCAGTT CTGCTCATGC TTAATGTCCA ACTTCCTTCG 421 AGGCTGTTCC TCTAAAAAGC CAGCCCAGGT ATCACAGGTA ACAAAGATCA GGAGACAATA 481 GCACTGGACA CTTCTCACAT TGGTATCATG ATAATGAGCT CTGTGAGTGT GTGTGTGTGT 541 GTGTGTGGTC CCGGGTATCA CACCTAAGGT CTGTGCATAC TTCCTAATTT TAAAACTATG 601 ATAACAAGAA TGATAGCAGT CATAGTGACT TAAAGTGGCC TTAAATGGCA CTTCAGTTGC 661 ATCTTGTGCT TCTTGAACTT ACAGTATCTG TTCCTTCCGT TTGTTACACT CAGTTTTATG 721 CCTCAGTAGA GATGGGGGTT GACCACCACA GCATCCAGAG AGTGAACTTT AGCCTCCCAA 781 TTCTCTAATA TATTTTTCTT TTTTTAAAAT GACATTATAA GATAGCTAGA AAGACTAGTT 841 GCTTGCACCA AAAAGTGATT TATTTTAATT TTGTGTGTGT GTGTGTGTCA AAAAGTATTA 901 AAAAAAAAAA GAACTCCTTT TTCCTCATTA AAAATACCTT ACTGGAGGCC TGGAGAGCTG 961 GCCCAGTGAT TAAGAGCACT TACTTCTATT GCAGAGGGAC CAGCAGGCAG TTGAAAGCCA 1021 CCATGTGTGC TTTGCTGGGA TCTGACCTGA TCATCTGCAG ACATTCGTTG CTCTCTCCAT 1081 TTCCCTCGTA CATACTCCAT CGATCCGTCC GTTCGTTTTT ATTTAAAAAA TACGGGCGC //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original	Tran, T.H., B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat. Immunol., 11, 148-154 (2010). PMID 19966806. [link to RRC of NBRP]

Resource search

Link

Other resources in our bank

mouse Aicda

External Database
Mouse Aicda

Reference sequence